Search Results
Your search for Hope matches 3187 pages
Showing 2601 - 2650ASCO Targets Health Disparities, Need for Research in Achieving Health Equity
The American Society of Clinical Oncology (ASCO), the Association of Black Cardiologists (ABC), and the Heart Failure Society of America (HSFA) recently held a Capitol Hill Briefing to draw attention to health disparities among minority and underserved patients and opportunities to achieve health...
Shorter Duration of Hormone Therapy Feasible in Localized High-risk Prostate Cancer
Men with localized high-risk prostate cancer treated with adjuvant radiotherapy had similar overall and disease-free survival when treated with 18 months of androgen deprivation therapy vs 36 months of androgen deprivation therapy, the current standard of care in this setting. These results were...
Why Is Stem Cell Transplant So Underused in Follicular Lymphoma?
Follicular lymphoma is the second most common subtype of non-Hodgkin lymphoma (NHL) in the United States. Of the nearly 70,000 new cases of NHL anticipated in 2013,1 approximately 7,000 to 13,000 (10%–19%) will be follicular lymphoma, by recent estimates.2-5 For many years, the median overall...
Top Five Things Oncologists Need to Know about Cancer in Older Adults
A workforce shortage of geriatricians and other health professionals certified in caring for older patients with cancer is colliding with the aging of the population and the increasing number of older Americans with cancer. After describing factors contributing to these dual challenges, Arti...
Déjà Vu Redux: Lessons from the SWOG-8516 Study in Aggressive Lymphomas
Joseph M. Connors, MD, authored a commentary in the June 25 issue of The ASCO Post inspired by a recent New England Journal of Medicine publication on dose-adjusted EPOCH-R chemotherapy (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) for primary mediastinal B-cell ...
Seeking Clarity on the PSA Story
My feature interview in the August 15, 2012, issue of The ASCO Post, entitled “Rethinking the Role of PSA Screening in Public Health”1 drew swift reaction from well-known figures in the prostate cancer field. The subsequent Letters to the Editor, three in all, constituted a two-pronged attack. They ...
I Overcame Cervical Cancer but Not Its Long-term Effects
In 1979, when I was just 35 years old, I started experiencing abnormal vaginal bleeding and lower back pain. When a Pap test came back normal, the gynecologist I saw said not to worry about anything, that I was fine. But I wasn’t fine. My symptoms quickly escalated, and I sought the opinion of...
Making the Science of Cancer Understandable to a Broad Audience
An educator and scientist for over 30 years, David Sadava, PhD, became interested in the science of cancer while on sabbatical from Claremont Colleges, where he was teaching courses in molecular biology and biotechnology, and went to the City of Hope Medical Center in Duarte, California, to study...
SIDEBAR: NCAA Athletes as 'SUNSPORT' Ambassadors
Consistent use of sunscreen is one of the key messages of SUNSPORT (Stanford University Network for Sun Protection, Organization, Research, and Teamwork). The program is geared towards reducing sun exposure among students playing in National Collegiate Athletics Association (NCAA) sports. “The...
Oncology Meetings
August Hematology and Medical Oncology Best PracticesAugust 15-22 • Arlington, VirginiaFor more information: www.gwumc.edu/cehp/hemoncbestpractices/ Best of ASCO® Los AngelesAugust 16-17 • Los Angeles, CaliforniaFor more information: boa.asco.org ISEH – Society for Hematology and Stem Cells 42nd...
Adolescents, Young Adults with Cancer Often Challenged By Unmet Needs Following Treatment
About 70,000 adolescents and young adults (AYAs) between the ages of 15 and 39 are diagnosed with cancer each year, and in the past 30 years, there has been little or no improvement in survival in this population. In addition to the disease itself, they face many other challenges: reentry into...
A Look Ahead: The Next Decade in Pediatric Oncology
The past 10 years have seen dramatic advances in cancer care, especially in better screening methods and earlier detection, genomic sequencing, and more effective therapies, which have led to increased survival rates in both childhood and adult cancers. According to the National Cancer Institute...
Oncology Meetings
September Georgia Society of Clinical Oncology 2013 GASCO Annual MeetingSeptember 6 • Atlanta, GeorgiaFor more information: www.gasco.us SGI Summit Turkey 2013: Innovations in Obstetrics and GynecologySeptember 6-8 • Istanbul, TurkeyFor more information: www.sgiturkey2013.org/ Breast Cancer...
Molecular Profiling Improves Classification of Nodal Peripheral T-Cell Lymphomas
One of the primary obstacles we face in caring for patients with peripheral T-cell lymphomas is a too often inadequate response to chemotherapy with low rates of progression-free and overall survival.1 And while more intensive treatment programs and the availability of novel agents give a greater...
Pharmacyclics' Reply
We acknowledge the letters submitted to The ASCO Post from a patient advocate and a chronic lymphocytic leukemia (CLL) patient enrolled on the RESONATE study (PCYC-1112-CA). At Pharmacyclics, we are committed to adhering to high scientific and ethical standards as we strive to develop novel...
The Oncologist as Author: On Guiding Patients Through Cancer
When Tumor Is the Rumor and Cancer Is the Answer is the guidebook to cancer that Kevin P. Ryan, MD, FACP, COL, USAF (ret) wished his patients had during his 30 years of practicing oncology. The book, recently published by AuthorHouse, is an authoritative, inspiring, and even philosophical guide for ...
Oncology Meetings
September Inflammation, Microbiota, and CancerSeptember 19-20 • Bethesda, MarylandFor more information: ncifrederick.cancer.gov/events/microbiota/agenda.asp Continuum Cancer Centers of New York Conference on Quality of Care in OncologySeptember 20 • New York, New YorkFor more information:...
The Trials and Tribulations of a Revolutionary Cancer Drug
A modest brass plaque above a booth in the Eagle Pub in Cambridge, notes, “On this spot, on February 28, 1953, Francis Crick and James Watson declared the discovery of DNA with these words: ‘We have discoverewd the secret of life.’” Announcing a major scientific advance over a pint of ale is a far...
Cancer: Survivors in Focus Photo Exhibit Honors Cancer Survivors
In June, the David J. Sencer Centers for Disease Control and Prevention (CDC) Museum in Atlanta, Georgia, opened a new photo exhibit featuring the faces of people living through and beyond a cancer diagnosis. The exhibit: Cancer: Survivors in Focus, tells the stories of cancer survivors while...
The Direction of Immunotherapy Over the Next Decade
The use of immunotherapy to target malignant cells in a variety of cancers—especially the PD-1 inhibitors lambrolizumab and nivolumab in the treatment of metastatic melanoma and the anti–PD-L1 agent MPDL3280A in the treatment of melanoma and lung, kidney, colorectal, and gastric cancers—made...
The BEATRICE Study: Where Does Targeting Breast Cancer Vasculature Stand in 2013?
Antiangiogenic strategies using the anti–vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab (Avastin) gained traction in breast cancer with the publication of the Eastern Cooperative Oncology Group (ECOG) 2100 trial in 2007. That study demonstrated a progression-free survival ...
Treatment of Relapse of Acute Leukemia Post-Transplant: Still Hope for Patients With Chemosensitive Disease
Disease recurrence is a devastating event after allogeneic hematopoietic stem cell transplantation as treatment for acute myeloid leukemia (AML). Median time to relapse is approximately 4 months and the majority of relapses occur within 2 years after transplant. The prognosis is usually poor....
A Great Privilege to Die Beneath an Open Sky
It was 1:00 AM, and my beeping pager awakened me. When you’re a surgical oncologist, you know that a page from your chief resident at this hour of the morning usually means someone may need to go to the operating room. And, yes, it was the chief resident about a patient in crisis. Except in this...
'Doing Nothing' Is Not an Option
I applaud The ASCO Post for continuing to raise awareness about futile medical care at the close of life with the recent publication of a commentary by Dr. Chandrakanth Are (“A Great Privilege to Die Beneath an Open Sky,” The ASCO Post, September 15, 2013, page 1). I would suggest, however, that we ...
What You Need to Know About E-Cigarettes
“I’ve seen a lot of puzzled people,” Alexander V. Prokhorov, MD, PhD, said, referring to people who see others using electronic or e-cigarettes. That puzzlement can go beyond wondering why people are smoking in public places and whether they are breaking the law, or just being annoying, to...
Oncology Meetings
October International Clinical Trials Workshop October 17-18 • Santiago, Chile For more information: www.asco.org/ASCOv2/About+ASCO/International+Affairs/International+Clinical+Trials+Workshops 64th Annual Scientific Meeting of The Royal Australian and New Zealand College of RadiologistsOctober...
Focus on the Wisconsin Association of Hematology & Oncology
The Wisconsin Association of Hematology & Oncology (WAHO) is among the youngest of ASCO’s State Affiliates. Formerly known as the Wisconsin Association of Medical Oncologists, WAHO was officially formed just 2 years ago and is already having an impact on oncologists and patients with cancer...
Protecting Hippocampus During Whole-Brain Radiation Substantially Reduces Rate of Cognitive Decline
Protecting the stem cells that reside in and around the hippocampus substantially reduces the rate of cognitive decline in patients during whole-brain radiotherapy without a significant risk of recurrence in that area of the brain, a new study shows. Results of the phase II clinical trial of...
Society Announces Candidates for ASCO Election
Fourteen distinguished ASCO members have been selected by the ASCO Nominating Committee as candidates for open leadership positions within the Society for the 2014 ASCO Election. Biographic information and interviews with each candidate, as well as instructions for casting a proxy ballot, will be...
Sheldon Davidson, MD: Helping Advance the Field of Oncology Through Philanthropy
Sheldon Davidson, MD, has been an ASCO member for nearly 30 years, and has been a donor to the Conquer Cancer Foundation since its origins as The ASCO Foundation nearly 15 years ago. As a practicing oncologist, Dr. Davidson’s explanation for why he has chosen to support the Conquer Cancer...
Comparative Effectiveness Research: Its Time Has Arrived
Reigning in the nation’s runaway medical costs was an underlying theme of President Obama’s health-care reform platform. Citing projects like The Dartmouth Atlas of Health Care, which documented large gaps in the quality, costs, and outcomes of health services around the country, the...
Ancient Chinese Military Tactics Might Help Win the War on Lung Cancer
At the 14th International Lung Cancer Congress, held recently in Huntington Beach, California, Tony S.K. Mok, MD, Professor of Clinical Oncology at the Chinese University of Hong Kong, was the honored recipient of the Bonnie J. Addario Lung Cancer Foundation Award. The award was presented by Ms....
Contemporary Studies Dispute Findings of Radiation-Induced Cardiotoxicity
At the 2013 Breast Cancer Symposium, studies suggested that with current radiotherapy techniques the mean radiation doses to the heart are much lower—and thus radiotherapy is presumably much safer—than findings suggested by an article published in The New England Journal of Medicine last spring.1...
Oncology Meetings
November Graft vs Host Disease National SymposiumNovember 1 • Independence, OhioFor more information: www.cowdenfoundation.org/gvhd-home/ Washington State Medical Oncology Society Fall 2013 Oncology ConferenceNovember 1 • Seattle, WashingtonFor more information: www.wsmos.org Quality Care...
Cardiovascular Risk Factors in Cancer Survivors
Armstrong et al evaluated the prevalence of self-reported hypertension, diabetes mellitus, dyslipidemia, and obesity and the incidence of self-reported major cardiac events such as coronary artery disease, heart failure, valvular disease, and arrhythmias in adult survivors of childhood cancer in...
International Cancer Corps Provides Valuable First-Time Volunteer Experience
Even as oncologists try to tackle the changing landscape of health care in the United States, many realize that both physicians and patients in this country are still in a better position than those fighting cancer abroad in low- and middle-income countries. In 2009, ASCO joined with Health...
ASCO's 2013 Top Five List in Oncology for Choosing Wisely Campaign
ASCO recognizes the importance of evidence-based cancer care and making wise choices in the diagnosis and management of patients with cancer. After careful consideration by experienced oncologists, ASCO annually highlights five categories of tests, procedures and/or treatments annually whose common ...
Illness Is Personal!
For clinicians and health service researchers striving to improve care for people living with life-threatening conditions, September was a sobering month. The Dartmouth Atlas group released a brief report on Trends in Cancer Care Near the End of Life1 showing that while the proportion of patients...
Finasteride for Prostate Cancer Prevention: Long-Term Results Disappointing but Reassuring
All medical care should seek to achieve one or more of three goals: to relieve suffering, to prevent future suffering, or to prolong life. Care for cancer is no exception, and minimizing suffering from cancer and prolonging life has primarily resulted from advances in treatment. Although there are...
SIDEBAR: Brian J. Druker, MD, Discusses Ponatinib
In an interview with The ASCO Post following FDA’s recommendation that sales of ponatinib (Iclusig) be suspended, (see here) Brian J. Druker, MD, Director of Oregon Health & Science University Knight Cancer Institute and JELD-WEN Chair of Leukemia Research, had concerns about obtaining the drug ...
Oncogene Addiction and the Rationale for Molecular Targeted Therapy in Lung Cancer
Over the past decade, Fadlo R. Khuri, MD, Professor and Roberto C. Goizueta Distinguished Chair of Hematology and Medical Oncology, and Deputy Director of the Winship Cancer Institute of Emory University, Atlanta, has focused his research and clinical career on investigating novel approaches in the ...
One Dose of HPV 16/18 Vaccine Produces Durable Response, Study Finds
Results from the Costa Rica HPV 16/18 Vaccine Trial indicate that 4-year efficacy against 12-month HPV 16/18 persistent infection was similarly high among women who received one, two, or the recommended three doses of the bivalent HPV16/18 L1 virus-like particle vaccine (Cervarix). The findings...
A New Gift to Add to Your List—One to Conquer Cancer
Conquering cancer requires the commitment, talent, and resources of all members of our community. It requires the innovation of researchers and the insight of clinicians, the courage of our worldwide community of patients and survivors, and it requires the generosity of everyone who believes in a...
Why We Give: ASCO Staff Members on Why They Support the Conquer Cancer Foundation
Lynne Blasi, Director, Patient Education and Advocacy, ASCO Why do you choose to support the Conquer Cancer Foundation? I support the Conquer Cancer Foundation because of the tremendous impact it has across so many vital areas. From funding grants for young researchers with innovative ideas,...
Improving Fertility Options for Patients With Cancer
Seven years ago, Teresa K. Woodruff, PhD, coined the term “oncofertility” to describe the melding of two medical specialties, oncology and reproductive endocrinology, with the goal of maximizing the reproductive potential of patients with cancer. Today, with Dr. Woodruff’s establishment of the...
Cetuximab Confers Survival Benefit in All-RAS Wild-Type Colorectal Tumors
The FIRE-3 study compared the two epidermal growth factor receptor (EGFR) antibodies, on top of chemotherapy, in the first-line treatment of metastatic colorectal cancer. A preplanned analysis of KRAS wild-type patients without RAS mutations, ie, “all-RAS wild-type,” showed overall survival to be...
Steven T. Rosen, MD, Named Provost and Chief Scientific Officer of City of Hope
City of Hope has selected Steven T. Rosen, MD, the Director of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University Feinberg School of Medicine, as its first Provost and Chief Scientific Officer. Dr. Rosen will set the scientific direction of City of Hope as it embarks on a...
Society for Integrative Oncology Is Helping to Advance Evidence-Based, Comprehensive Integrative Health Care
Heather Greenlee, ND, PhD, was named President of the Society for Integrative Oncology (SIO) at the organization’s 10th International Conference in October. Dr. Greenlee is Assistant Professor in the Department of Epidemiology at the Mailman School of Public Health at Columbia University in New...
A New Gift to Add to Your List—One to Conquer Cancer
Conquering cancer requires the commitment, talent, and resources of all members of our community. It requires the innovation of researchers and the insight of clinicians, the courage of our worldwide community of patients and survivors, and it requires the generosity of everyone who believes in a...
Consent Is Informed and Shared, But Is It Compassionate?
A 72-year-old, obese male patient and a poor operative candidate is diagnosed with esophageal carcinoma. He has multiple comorbidities and a past history of colon carcinoma. His staging workup, which included a colonoscopy, revealed recurrent colon carcinoma. Thus, we have a patient who we...
